Bluebird bio, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.
The following report cites that, “The company has completed a single-dose toxicology study of our Lenti-D product candidate in immunodeficient mice following a single intravenous administration.“(Page 19) Read the full document.
Bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA. [Source: MarketWatch]